Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Filings indexed 275 across all filing types
Latest filing 2023-09-12 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
신규시설투자등(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory disclosure (자율공시) regarding a new facility investment (신규시설투자) by Pharmicell. It details the investment amount, purpose (GMP factory expansion), and timeline. Since this is a specific announcement of a capital expenditure/investment project rather than a financial report or a general regulatory notice, it fits best under the 'Capital/Financing Update' category, which covers company financing and capital structure/investment activities.
2023-09-12 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Pharmicell Co., Ltd., covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial data, business operations, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal disclosure of a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between Pharmicell and LG Chem. It details the contract value, duration, and counterparty. Since this is a specific regulatory disclosure regarding a commercial contract and does not fit into categories like M&A, financial reports, or governance, it falls under the general regulatory filing category.
2023-06-27 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Pharmicell regarding a 'Single Sale/Supply Contract' amendment. It details a change in the contract end date for a supply agreement with Thermo Fisher Scientific. Since this is a specific regulatory disclosure regarding a commercial contract and does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2023-05-17 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Pharmicell regarding a 'Single Sales/Supply Contract' amendment. It details a change in the contract end date for a supply agreement with Thermo Fisher Scientific. Since this is a specific regulatory disclosure regarding a material contract update (a 'Correction Report' or 'Jeong-jeong-sin-go' in Korean regulatory terms) that does not fit into specific categories like M&A or Dividend announcements, it falls under the general regulatory filing category.
2023-05-17 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Pharmicell Co., Ltd. covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial data, business operations, management discussions, and capital structure information. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year that contains actual financial statements or substantive financial data is classified as an Interim / Quarterly Report (IR). Q1 2023
2023-05-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.